Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21252887 | 0.80 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2FFAR4FFAR1 | |
| SCHEMBL5278613 | 0.79 | SMN1; SMN2 (0.56) | NPC1RAB9ASMN1; SMN2FFAR4FFAR1 | |
| SCHEMBL3340113 | 0.78 | CES2 (0.50) | ALDH1A1PKM | |
| SCHEMBL10454721 | 0.78 | CTSD (0.50) | NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL20179628 | 0.75 | HPGD (0.41) | NPC1RAB9ACTSLALDH1A1LMNA | |
| SCHEMBL27709578 | 0.74 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2FFAR4FFAR1 | |
| SCHEMBL2532235 | 0.73 | TSHR (0.54) | NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL21807118 | 0.73 | SMN1; SMN2 (0.43) | NPC1RAB9ASMN1; SMN2FFAR4CTSL | |
| SCHEMBL12806480 | 0.73 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2FFAR4FFAR1 | |
| SCHEMBL1020142 | 0.73 | SMN1; SMN2 (0.49) | NPC1RAB9ASMN1; SMN2KDM4ECTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861379-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-05 | — | — | EP | disclosed |
| US-20060229305-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2006-10-12 | — | — | US | disclosed |
| WO-2006100100-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229305-A1 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents | PTGES, TNF, DHPS | NPC1 1612/4885RAB9A 2447/4885SMN1; SMN2 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.